Justus Baron

Dr. Justus Baron is a Senior Research Associate in Economics at Northwestern University, Pritzker School of Law. Dr. Baron’s research focuses on technological innovation, standardization, and Intellectual Property Rights (IPR). Dr. Baron has written scholarly articles published in leading outlets, such as Research Policy, Antitrust Law Journal, and the International Journal of Industrial Organization, as well as several comprehensive policy reports for the European Commission. Dr. Baron has created the Searle Center Database, a collection of datasets on technology standards and SEPs used by numerous scholars in various fields.

Dr. Baron was a member of the European Commission’s Expert Group on Standard Essential Patents (SEP), and currently is the lead researcher of a consortium assisting the European Commission with an Impact Assessment on SEPs. Dr. Baron also frequently writes on standardization policy and the governance of standards organizations. Dr. Baron was one of the authors of a comprehensive EU report on SDO governance and SDO decision-making on IPR, has briefed the President’s National Security Telecommunications Advisory Committee Standards Subcommittee on the importance and measurement of leadership in standardization, and currently participates in a research project of the CERRE think tank on the EU’s Standardization Strategy.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More